UOC
PHAT icon

UBS O'Connor’s Phathom Pharmaceuticals PHAT Stock Holding History

UBS O'Connor’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-28,583
Closed -$304K – 618
2024
Q1 		$304K Sell
28,583
-14,626
-34% -$124K 0.01% 367
2023
Q4 		$394K Sell
43,209
-74,071
-63% -$638K 0.01% 372
2023
Q3 		$1.22M Sell
117,280
-23,000
-16% -$315K 0.02% 309
2023
Q2 		$2.01M Buy
140,280
+40,187
+40% +$463K 0.04% 290
2023
Q1 		$715K Buy
+100,093
New +$879K 0.02% 436
2022
Q4 		– Sell
-154,093
Closed -$1.71M – 242
2022
Q3 		$1.71M Buy
154,093
+27,000
+21% +$257K 0.02% 664
2022
Q2 		$1.07M Buy
+127,093
New +$1.31M 0.01% 751

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

UBS O'Connor's PHAT Position: Q2 2024 in Review

UBS O'Connor sold out of Phathom Pharmaceuticals (PHAT) in Q2 2024, closing a stake of 28,583 shares — an estimated $304K sold.

UBS O'Connor first reported a position in PHAT in Q2 2022 and held it in 7 quarters. The position peaked at $2.01M in Q2 2023. 114 funds tracked by Wall St. Rank hold PHAT as of Q2 2024.

  • UBS O'Connor reported no remaining Phathom Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • UBS O'Connor sold 28,583 Phathom Pharmaceuticals shares in Q2 2024, an estimated $304K.
  • UBS O'Connor first reported a position in Phathom Pharmaceuticals in Q2 2022 and held it in 7 quarters.
  • UBS O'Connor's Phathom Pharmaceuticals position peaked at $2.01M in Q2 2023.
  • 114 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2024.

Based on UBS O'Connor's 13F filing for Q2 2024, filed 14 Aug 2024.